ライフサイエンスコーパス: micrometastasis

1 n aid in the visualization of ovarian cancer micrometastasis.

2 because of the associated increased risk of micrometastasis.

3 be overlooked during SLND as they may harbor micrometastasis.

4 th cisplatin to enhance suppression of liver micrometastasis.

5 ften by just one growth-restricted dangerous micrometastasis.

6 trigel plug angiogenesis, and uveal melanoma micrometastasis.

7 ecurrence of established cancer, and to find micrometastasis.

8 androgen-independent growth, accompanied by micrometastasis.

9 (subsequent outgrowth) of lung experimental micrometastasis.

10 the effect of inhibiting VEGF on tumor cell micrometastasis.

11 nt IFN-alpha 2b results in decreased hepatic micrometastasis and increased survival time through incr

12 However, the clinical relevance of SLN micrometastasis and isolated tumour cells remains unclea

13 owing at various secondary sites to generate micrometastasis and metastatic colonization than control

14 fraction of cancer cells is able to generate micrometastasis and metastatic colonization.

15 but not parental cells) were capable of lung micrometastasis and of binding exogenously-added hyaluro

16 p120 isoforms, is predictive of renal tumor micrometastasis and systemic progression, following neph

17 ts of cancer progression (local invasion and micrometastasis) and may no longer be required once meta

18 layer or small cluster of cells simulating a micrometastasis, and little effect in a sphere analogous

19 rognosis similar to that associated with SLN micrometastasis, and the number of positive qRT biomarke

20 ualization of intraperitoneal ovarian cancer micrometastasis as small as 100 mum with optimal resolut

21 implanted human PC3-M PCa cells formed lung micrometastasis by 4 weeks in >80% of inbred athymic mic

22 The depth to which metastasis and micrometastasis could be imaged depended on their size.

23 l cancers, perhaps because of more effective micrometastasis eradication and reduced risk of incomple

24 -mediated signaling, LUAD cell survival, and micrometastasis expansion in hyaluronan-rich microenviro

25 atic potential of tumor cells by quantifying micrometastasis formation within the ovarioles of adult

26 STIC unexpectedly supported the lesion as a micrometastasis from the associated UEC.

27 Patients with a micrometastasis in a lymph node were later allowed with

28 he growth of ocular melanoma and its hepatic micrometastasis in a mouse ocular melanoma model.

29 ne the clinical significance of colon cancer micrometastasis in sentinel lymph nodes.

30 rly detection of high-risk breast cancer and micrometastasis in the clinic.

31 for the first time small, apparently dormant micrometastasis in the liver of patients with uveal mela

32 The procedure has improved the diagnosis of micrometastasis in the regional tumor-draining lymph nod

33 nderstanding and management of some melanoma micrometastasis in the sentinel node.

34 with primary breast tumors < or = 2.0 cm and micrometastasis in the SLN.

35 f micrometastases, and finally the growth of micrometastasis into macroscopic tumors.

36 If SLN micrometastasis is used to determine the need for furthe

37 ection of high-risk breast cancer, including micrometastasis, is critical in tailoring appropriate an

38 olvement was 7% when the sentinel node had a micrometastasis (< or =2 mm), compared with 55% when the

39 it equally as clear when to perform ALND if micrometastasis (Mi) or isolated tumor cells (ITCs) are

40 r cell lines, and in the GW-39 human colonic micrometastasis model in vivo.

41 ppressed in vitro growth and in vivo hepatic micrometastasis of ocular melanoma cells.

42 sion of PEDF inhibits the growth and hepatic micrometastasis of ocular melanoma.

43 ing was used for quantification of growth of micrometastasis on the liver and stomach.

44 Pathologists' distinction between micrometastasis (pN1mi) and isolated tumor cells [ITC; p

45 be the underlying determinant of spontaneous micrometastasis produced by these cells when compared wi

46 turnover rate, antigen expression level, and micrometastasis size on antibody penetration and retenti

47 Two of the 16 patients with IMSLNs had micrometastasis to IMSLN; 1 patient died and the other c

48 Angiogenesis-mediated progression of micrometastasis to lethal macrometastasis is the major c

49 aticoduodenectomy specimen lymph nodes had a micrometastasis to one perigastric lymph node.

50 or primary tumor outgrowth but that promotes micrometastasis to the lungs at the very earliest stages

51 tients with primary tumors < or = 2.0 cm and micrometastasis to the SLN had remaining axillary lymph

52 ate that PEG tuning can provide control over micrometastasis tracking with high tumor-to-background c

53 010 vs 18 for years 1992-2001, P < .001), LN micrometastasis vs macrometastasis (20 vs 19, P = .005),

54 The mechanism(s) of this facilitated micrometastasis was analyzed in an experimental metastas

55 Micrometastasis was detected in 1 of 5 sentinel lymph no

56 us 1.0, P = 0.02); however, the incidence of micrometastasis was statistically similar in both HSA an

57 f the ocular tumor and the number of hepatic micrometastasis were compared between the mice inoculate

58 he ocular melanoma and the number of hepatic micrometastasis were decreased and microvessel density w

59 ng patients with melanoma and regional nodal micrometastasis who may benefit from full nodal basin re

60 icellular spheroids are an in vitro model of micrometastasis whose adhesive abilities have not been e

61 capability of CREKA-Tris(Gd-DOTA)3 to detect micrometastasis with MRI in co-registration with high-re